![The ProciseDx instrument is about the size of a shoe box and can provide diagnostics results in as little as 2 minutes from a finger prick drop of blood. The ProciseDx instrument is about the size of a shoe box and can provide diagnostics results in as little as 2 minutes from a finger prick drop of blood.](https://www.finsmes.com/wp-content/uploads/2021/07/image-50.jpeg)
ProciseDx, a San Diego CA-based in vitro diagnostics (IVD) company, raised $13M in convertible note financing.
Participants included existing major shareholders (Nestlé Heath Science, Biosynex SA) management and new investors.
The company intends to use the funds to move forward with FDA submissions for the platform and to expand the test menu for gastroenterologists.
Led by CEO and CSO Dr. Larry Mimms and President and CFO Peter Westlake, ProciseDx provides a broad portfolio of rapid diagnostic tests for the physician’s office, which use a finger prick blood sample or a stool sample and have a turn-around time of 2-5 minutes. ProciseDx has obtained CE Mark on its instrument and on four gastroenterology (GI) assays which were launched in Q3 2020. The company has established distribution relationships in more than 15 countries in Europe, Middle East and Africa (EMEA) and expects to continue its market expansion for the rest of 2021. Already over 100 instruments have been shipped to EMEA and further growth is expected in the second half of 2021. The company expects revenues of between $2 million and $3 million for 2021.
ProciseDx has submitted a 510k application to the FDA for its instrument and Procise CRP assay. Further submissions for additional assays are expected in 2021 and will create a compelling menu for GI’s in the US.
FinSMEs
19/07/2021